Møller B, Weedon-Fekjaer H, Hakulinen T, Tryggvadóttir L, Storm H H, Talbäck M, Haldorsen T
Cancer Registry of Norway, Institute of population-based cancer research, Montebello, N-0310 Oslo, Norway.
Eur J Cancer Prev. 2005 Apr;14(2):117-28. doi: 10.1097/00008469-200504000-00007.
Introducing an organized mammographic screening programme affects the breast cancer incidence rate in a population. The diagnosis is advanced in time, and initially, an increase will occur in the number of cases, followed by a drop in the rate when women leave the programme. The aim of this study was to quantify the potential effects that mammographic screening programmes have on breast cancer incidence. In addition, we wanted to investigate how the incidence of breast cancer varies between different birth cohorts, age groups and time periods in the five Nordic countries Finland, Denmark, Iceland, Norway and Sweden, adjusting for the effects of the screening programmes. Time trends were analysed over the period 1978-1997, using age-period-cohort models. In Sweden, the rates more than doubled (relative risk (RR)=2.20, 95% confidence interval (CI) 1.8-2.6) in women offered screening for the first time compared with women not offered screening. The risk remained elevated (RR=1.34, 95% CI 1.2-1.6) for women who were continued to be offered screening, compared with women who were not offered screening. Finally, the rates dropped (RR=0.68, 95% CI 0.6-0.8) when the women left the programme. This indicates that screening advances the time of diagnosis, which is a prerequisite to subsequent reduction in mortality. Analysis of secular trends, corrected for the influence of screening, showed that the rates in Finland increased by 13% per 5-year period, with a more modest increase in the other countries. There were strong cohort effects in all Nordic countries, and the risk seemed to be flattening for the youngest cohorts in most of the countries.
引入有组织的乳腺钼靶筛查计划会影响人群中的乳腺癌发病率。诊断时间提前,最初病例数会增加,随后当女性退出该计划时发病率会下降。本研究的目的是量化乳腺钼靶筛查计划对乳腺癌发病率的潜在影响。此外,我们想研究在芬兰、丹麦、冰岛、挪威和瑞典这五个北欧国家中,不同出生队列、年龄组和时间段内乳腺癌发病率如何变化,并对筛查计划的影响进行调整。使用年龄-时期-队列模型分析了1978年至1997年期间的时间趋势。在瑞典,首次接受筛查的女性与未接受筛查的女性相比,发病率增加了一倍多(相对风险(RR)=2.20,95%置信区间(CI)1.8 - 2.6)。与未接受筛查的女性相比,继续接受筛查的女性风险仍然升高(RR = 1.34,95% CI 1.2 - 1.6)。最后,当女性退出该计划时,发病率下降(RR = 0.68,95% CI 0.6 - 0.8)。这表明筛查提前了诊断时间,这是随后降低死亡率的前提条件。对经筛查影响校正后的长期趋势分析表明,芬兰的发病率每5年增加13%,其他国家的增幅较小。所有北欧国家都有很强的队列效应,在大多数国家,最年轻队列的风险似乎趋于平稳。